← Back
Data updated: Mar 10, 2026
HYBIO
CardiovascularNeurologyOncology
HYBIO is a generic drug manufacturer focused on Cardiovascular, Neurology, Oncology.
2020
Since
2
Drugs
-
Trials
13
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
GLATIRAMER ACETATE 2026-02-11
GLATIRAMER ACETATE 2026-02-11
GLATIRAMER ACETATE 2025-12-31
EPTIFIBATIDE 2025-06-13
Labeling
GLATIRAMER ACETATE 2025-05-16
Labeling
GLATIRAMER ACETATE 2025-05-16
Labeling
GLATIRAMER ACETATE 2025-05-07
EPTIFIBATIDE 2025-03-25
Labeling
EPTIFIBATIDE 2025-01-15
Labeling
EPTIFIBATIDE 2024-11-19
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Cardiovascular 46%
1 drugs
Neurology 46%
1 drugs
Oncology 8%
0 drugs Phase 1: 1
Pipeline Strength Pro
Loading...
Active (2)
Discontinued (0)
Company Info
- First Approval
- 2020-03-20
- Latest
- 2026-02-11
- Applications
- 3